


TrkA-IN-3

Cat. No.:	HY-151948		
CAS No.:	3026111-73-6		
Molecular Formula:	C ₂₄ H ₁₇ F ₃ N ₄ O ₃		
Molecular Weight:	466.41		
Target:	Trk Receptor		
Pathway:	Neuronal Signaling; Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (107.20 mM; Need ultrasonic)			
		Solvent	Mass	
		Concentration	1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	2.1440 mL	10.7202 mL	21.4404 mL
	5 mM	0.4288 mL	2.1440 mL	4.2881 mL
	10 mM	0.2144 mL	1.0720 mL	2.1440 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	TrkA-IN-3 is a potent, subselective and allosteric TrkA inhibitor, with an IC ₅₀ of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC. TrkA-IN-3 can be used for the research of pain ^[1] .
IC₅₀ & Target	TrkA 22.4 nM (IC ₅₀)
In Vitro	TrkA-IN-3 (compound 5) demonstrates 73.9% and 64.8% of kinase inhibition towards TrkA at concentrations of 1 μM and 0.1 μM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA